Results 81 to 90 of about 3,754 (109)

Immune modulation for β-cell replacement in type 1 diabetes. [PDF]

open access: yesFront Immunol
Yang Q, Song Y, Markmann JF, Lei J.
europepmc   +1 more source

Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation

Journal of Leukocyte Biology, 1992
Abstract Expression of decay-accelerating factor (DAF or CD55) and of CD59 during hematopoietic cell development in normal bone marrow and on peripheral blood leukocytes were characterized by three-color immunofluorescence experiments.
L W, Terstappen   +3 more
openaire   +4 more sources

Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer

Journal of Gastrointestinal Surgery, 2001
Despite radical surgery, the prognosis for colorectal cancer patients with liver metastases has not changed markedly. Furthermore, no standard adjuvant therapeutic regimen has been developed. Adjuvant therapy with monoclonal antibodies (e.g., against 17-1A), which has been shown to be effective in preventing metastatic relapse in patients with Dukes' C
S B, Hosch   +9 more
openaire   +2 more sources

Complete determination of disulfide bonds localized within the short consensus repeat units of Decay accelerating factor (CD55 antigen)

Biochimica et Biophysica Acta (BBA) - General Subjects, 1992
Decay accelerating factor (DAF) has 4 SCR (short consensus repeat) units. Each SCR unit consists of approx. 60 amino acids characterized by having four conserved cysteine residues and several other highly conserved residues which include proline, tryptophan, tyrosine/phenylalanine and glycine.
Y, Nakano   +5 more
openaire   +2 more sources

A Bispecific Monoclonal Antibody Directed Against Both the Membrane-Bound Complement Regulator CD55 and the Renal Tumor-Associated Antigen G250 Enhances C3 Deposition and Tumor Cell Lysis by Complement

The Journal of Immunology, 1998
Abstract Tumor cells may inhibit the induction of a complement-mediated inflammatory response through overexpression of membrane-bound regulators of complement activation. Therefore, it is of interest to determine the most efficient approach to block these membrane-bound complement regulators on tumor cells.
V T, Blok   +6 more
openaire   +2 more sources

Bi-specific monoclonal antibodies directed against CD55 and a cell-surface antigen and their effect on human renal tumor cells

Immunology Letters, 1997
V.T. Blok   +7 more
openaire   +2 more sources

Bispecific antibody against CD55 and an antigen on cervical carcinoma cells induces C3b deposition and lysis

Immunopharmacology, 2000
K.A. Gelderman   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy